lucanthone hydrochloride has been researched along with phosphorylcholine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Mol, M; Shinde, S; Singh, S | 1 |
| Eissa, MM; El-Azzouni, MZ; El-Khordagui, LK; El-Moslemany, RM; Ramadan, AA | 1 |
| Abdel Bary, A; Abdel Salam, SA; Eissa, MM; El-Azzouni, MZ; El-Khordagui, LK; El-Moslemany, RM | 1 |
3 other study(ies) available for lucanthone hydrochloride and phosphorylcholine
| Article | Year |
|---|---|
Regulatory networks, genes and glycerophospholipid biosynthesis pathway in schistosomiasis: a systems biology view for pharmacological intervention.
Topics: Amino Acid Sequence; Cytidine Diphosphate Choline; Drug Discovery; Gene Regulatory Networks; Glycerophospholipids; Host-Parasite Interactions; Humans; Metabolic Networks and Pathways; Models, Molecular; Molecular Docking Simulation; Molecular Sequence Data; Nucleotidyltransferases; Phosphorylcholine; Protein Structure, Tertiary; Schistosomiasis; Schistosomicides; Systems Biology | 2014 |
Miltefosine lipid nanocapsules: Intersection of drug repurposing and nanotechnology for single dose oral treatment of pre-patent schistosomiasis mansoni.
Topics: Administration, Oral; Animals; Disease Models, Animal; Drug Repositioning; Granuloma; Liver; Mice; Nanocapsules; Nanotechnology; Phosphorylcholine; Praziquantel; Schistosoma mansoni; Schistosomiasis mansoni; Schistosomicides | 2016 |
Single oral fixed-dose praziquantel-miltefosine nanocombination for effective control of experimental schistosomiasis mansoni.
Topics: Administration, Oral; Animals; Disease Models, Animal; Drug Combinations; Drug Compounding; Female; Humans; Male; Mice; Nanocapsules; Phosphorylcholine; Praziquantel; Schistosoma mansoni; Schistosomiasis mansoni; Schistosomicides | 2020 |